These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27766627)

  • 1. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.
    Latifoltojar A; Hall-Craggs M; Rabin N; Popat R; Bainbridge A; Dikaios N; Sokolska M; Rismani A; D'Sa S; Punwani S; Yong K
    Br J Haematol; 2017 Jan; 176(2):222-233. PubMed ID: 27766627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
    Latifoltojar A; Hall-Craggs M; Bainbridge A; Rabin N; Popat R; Rismani A; D'Sa S; Dikaios N; Sokolska M; Antonelli M; Ourselin S; Yong K; Taylor SA; Halligan S; Punwani S
    Eur Radiol; 2017 Dec; 27(12):5325-5336. PubMed ID: 28656463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Early Treatment Response in Multiple Myeloma Using MY-RADS Total Burden Score, ADC, and Fat Fraction From Whole-Body MRI: Impact of Anemia on Predictive Performance.
    Dong H; Huang W; Ji X; Huang L; Zou D; Hao M; Deng S; Shen Z; Lu X; Wang J; Song Z; Zhang X; Xue H; Xia S
    AJR Am J Roentgenol; 2022 Feb; 218(2):310-319. PubMed ID: 34523949
    [No Abstract]   [Full Text] [Related]  

  • 4. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study.
    Wu C; Huang J; Xu WB; Guan YJ; Ling HW; Mi JQ; Yan H
    Acad Radiol; 2018 Jul; 25(7):904-914. PubMed ID: 29373210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: A large single-center cohort study.
    Zhang Y; Xiong X; Fu Z; Dai H; Yao F; Liu D; Deng S; Hu C
    Eur J Radiol; 2019 Nov; 120():108695. PubMed ID: 31589995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI.
    Takasu M; Kondo S; Akiyama Y; Takahashi Y; Maeda S; Baba Y; Kawase T; Ichinohe T; Awai K
    PLoS One; 2020; 15(2):e0229607. PubMed ID: 32106239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Response Assessment in Multiple Myeloma: Histogram Analysis of Total Tumor Apparent Diffusion Coefficient based on Whole-body Diffusion-weighted MR Imaging.
    Gao Y; Wang Q; Zhang L; Li S; Liu D; Wang S; Zhu J; Zhang H; Xie S; Xia S; Huang W; Xue H; Li J
    J Magn Reson Imaging; 2024 Sep; 60(3):1051-1060. PubMed ID: 38088500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response.
    Park HY; Kim KW; Yoon MA; Lee MH; Chae EJ; Lee JH; Chung HW; Yoon DH
    Cancer Imaging; 2020 Jan; 20(1):14. PubMed ID: 32000858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
    Dutoit JC; Vanderkerken MA; Verstraete KL
    Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma.
    Horger M; Fritz J; Thaiss WM; Ditt H; Weisel K; Haap M; Kloth C
    Skeletal Radiol; 2018 Mar; 47(3):351-361. PubMed ID: 29222688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent diffusion coefficient maps integrated in whole-body MRI examination for the evaluation of tumor response to chemotherapy in patients with multiple myeloma.
    Bonaffini PA; Ippolito D; Casiraghi A; Besostri V; Franzesi CT; Sironi S
    Acad Radiol; 2015 Sep; 22(9):1163-71. PubMed ID: 26182979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma.
    Lacognata C; Crimì F; Guolo A; Varin C; De March E; Vio S; Ponzoni A; Barilà G; Lico A; Branca A; De Biasi E; Gherlinzoni F; Scapin V; Bissoli E; Berno T; Zambello R
    Clin Radiol; 2017 Oct; 72(10):850-857. PubMed ID: 28587715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging.
    Barwick T; Orton M; Koh DM; Kaiser M; Rockall A; Tunariu N; Blackledge M; Messiou C
    Br J Radiol; 2021 Apr; 94(1120):20200682. PubMed ID: 33733812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma.
    Koutoulidis V; Terpos E; Papanikolaou N; Fontara S; Seimenis I; Gavriatopoulou M; Ntanasis-Stathopoulos I; Bourgioti C; Santinha J; Moreira JM; Kastritis E; Dimopoulos MA; Moulopoulos LA
    Radiology; 2022 Jul; 304(1):137-144. PubMed ID: 35380497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analysis of Whole-Body MRI for Accessing the Degree of Diffuse Infiltration Patterns and Identifying High Risk Cases of Newly Diagnosed Multiple Myeloma.
    Sun M; Wang L; Wang C; Ma J; Wang W; Lin L; Ren C; Zhang Y; Cheng J
    J Magn Reson Imaging; 2024 Jun; 59(6):2035-2045. PubMed ID: 37675995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI.
    Winfield JM; Poillucci G; Blackledge MD; Collins DJ; Shah V; Tunariu N; Kaiser MF; Messiou C
    Eur Radiol; 2018 Apr; 28(4):1687-1691. PubMed ID: 29134357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.
    Lin C; Luciani A; Belhadj K; Deux JF; Kuhnowski F; Maatouk M; Beaussart P; Cuenod CA; Haioun C; Rahmouni A
    Radiology; 2010 Feb; 254(2):521-31. PubMed ID: 20093523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma.
    Wang J; Zhang B; Zhang R; Zhang L; Jiang W; Jiang Y
    Medicine (Baltimore); 2021 Sep; 100(35):e27131. PubMed ID: 34477159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma.
    Lai AYT; Riddell A; Barwick T; Boyd K; Rockall A; Kaiser M; Koh DM; Saffar H; Yusuf S; Messiou C
    Eur Radiol; 2020 Jan; 30(1):320-327. PubMed ID: 31267214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.